<DOC>
	<DOCNO>NCT00309660</DOCNO>
	<brief_summary>Treatment PPARgamma ligands show reduces intestinal inflammation murine model colitis . The aim study evaluate effect treatment local PPARgamma ligand ( rosiglitazone ) distal ulcerative colitis.The patient treat rosiglitazone enema , day , fourteen day . Disease activity assess treatment endoscopical clinical activity score .</brief_summary>
	<brief_title>Treatment With Local PPARgamma Ligand Distal Ulcerative Colitis</brief_title>
	<detailed_description />
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<mesh_term>Rosiglitazone</mesh_term>
	<criteria>Distal ulcerative colitis ( Mayo Clinical Score &gt; 7 ) Age &gt; 18 year Written consent Age &lt; 18 year Severe ulcerative colitis Systemic treatment steroid azathioprin within last 3 month Known liver kidney disease Severe heart failure Pregnancy breast feeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2006</verification_date>
	<keyword>PPARgamma ligand</keyword>
	<keyword>Rosiglitazone</keyword>
	<keyword>Enema</keyword>
</DOC>